Skip to main content

Main menu

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
      • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
  • BMJ Journals

User menu

  • Login

Search

  • Advanced search
  • BMJ Journals
  • Login
  • Facebook
  • Twitter
JIM

Advanced Search

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising

Correspondence on ‘COVID-19 vaccine efficacy in a rapidly changing landscape’

Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
DOI: 10.1136/jim-2022-002587 Published 15 August 2022
Rujittika Mungmunpuntipantip
1 Private Academic Consultant, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rujittika Mungmunpuntipantip
Viroj Wiwanitkit
2 Department of Community Medicine, D Y Patil Medical College, Kolhapur, Maharashtra, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Dear Editor,

We would like to comment on the publication ‘COVID-19 vaccine efficacy in a rapidly changing landscape’.1 A very small number of persons will still exhibit symptoms, require hospitalization, or pass away from COVID-19, according to Baer and Tran’s prediction.1 Therefore, it is critical to identify and thoroughly characterize the impact of a specific mutation for the pathogenesis of SAR-CoV-2. As the pandemic spreads, we should keep up our efforts to sequence and monitor SARS-CoV-2 evolution and modify vaccine plans as necessary.1

Due to the dangerous nature of COVID-19 and the vast spectrum of clinical symptoms it causes, immunization is crucial for efficient illness management. The vaccine’s effectiveness is influenced by a number of variables. Since an asymptomatic COVID-19 may commonly have a puzzling effect, the data that are now available may be incomplete.2 However, it must consider the possibility of asymptomatic COVID-19 in the populations being studied. Asymptomatic infections may become symptomatic during the observation period, changing the prognosis. The history of infection, which is a key factor in predicting the clinical course of the immunological response to infection and immunization, cannot be used to rule out COVID-19 silent infections.

Finally, it should be noted that the type of vaccination used and the manner of delivery both affect the vaccine’s effectiveness. There are many different vaccination types available today, and the methods of delivery vary, depending on the country. Many nations still use the inactivated COVID-19 vaccine, which is no longer efficacious, and heterologous mixing immunization. Low vaccine efficacy could be caused by an additional method of delivery, and this could be connected to the problem with the newly discovered COVID-19 variation.

Ethics statements

Patient consent for publication

Not applicable.

Ethics approval

Not applicable.

Footnotes

  • Contributors RM: 50% ideas, writing, analysis and final approval for submission. VW: 50% ideas, supervision and final approval for submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

References

  1. ↵
    1. Baer SL ,
    2. Tran S
    . COVID-19 vaccine efficacy in a rapidly changing landscape. J Investig Med 2022;70:1327–8.doi:10.1136/jim-2022-002520 pmid:http://www.ncbi.nlm.nih.gov/pubmed/35768142
    OpenUrlFREE Full Text
  2. ↵
    1. Joob B ,
    2. Wiwanitkit V
    . Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health 2020;53:70.doi:10.3961/jpmph.20.065 pmid:http://www.ncbi.nlm.nih.gov/pubmed/32268458
    OpenUrlPubMed
PreviousNext
Back to top
Vol 70 Issue 6 Table of Contents
Journal of Investigative Medicine: 70 (6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • AFMR Highlights
  • Front Matter (PDF)
Email

Thank you for your interest in spreading the word on JIM.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Correspondence on ‘COVID-19 vaccine efficacy in a rapidly changing landscape’
(Your Name) has sent you a message from JIM
(Your Name) thought you would like to see the JIM web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Correspondence on ‘COVID-19 vaccine efficacy in a rapidly changing landscape’
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
Journal of Investigative Medicine Aug 2022, 70 (6) 1442; DOI: 10.1136/jim-2022-002587

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Cite This
  • APA
  • Chicago
  • Endnote
  • MLA
Loading
Correspondence on ‘COVID-19 vaccine efficacy in a rapidly changing landscape’
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
Journal of Investigative Medicine Aug 2022, 70 (6) 1442; DOI: 10.1136/jim-2022-002587
Download PDF

Share
Correspondence on ‘COVID-19 vaccine efficacy in a rapidly changing landscape’
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
Journal of Investigative Medicine Aug 2022, 70 (6) 1442; DOI: 10.1136/jim-2022-002587
Reddit logo Twitter logo Facebook logo Mendeley logo
Respond to this article
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Article
    • Ethics statements
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Correspondence on ‘Low-dose thrombolysis for submassive pulmonary embolism’ by Yilmaz and Uzun
  • Correspondence on ‘Prospective predictive performance comparison between clinical gestalt and validated COVID-19 mortality scores’ by Soto-Mota et al
Show more Letter to the editor

Similar Articles

 

CONTENT

  • Latest content
  • Current issue
  • Archive
  • Sign up for email alerts
  • RSS

JOURNAL

  • About the journal
  • Editorial board
  • Subscribe
  • Thank you to our reviewers
  • American Federation for Medical Research

AUTHORS

  • Information for authors
  • Submit a paper
  • Track your article
  • Open Access at BMJ

HELP

  • Contact us
  • Reprints
  • Permissions
  • Advertising
  • Feedback form

© 2023 American Federation for Medical Research